Latest Reimbursement News

Page 5 of 50
Telix reported US$245 million in unaudited third-quarter revenue, with Precision Medicine sales up 30% and full-year revenue and other income still expected to exceed US$1 billion. The quarter also advanced the proposed US$1.65 billion ITM merger, added FDA-approved Pixclara to the commercial portfolio and narrowed the R&D spending range.
Ada Torres
Ada Torres
21 Oct 2026
Iondrive received $3.765 million in grant cash during FY2026, including $3.691 million from the Australian Government’s Industry Growth Program. The company has deferred $1.671 million of that funding until further eligible pilot plant expenditure is incurred.
Victor Sage
Victor Sage
21 Oct 2026
EBR Systems has submitted its WiSE wireless cardiac pacing system for Australian regulatory approval, opening a potential second commercial market after the United States. The application has entered a priority review pathway, but neither approval nor an assessment timetable is guaranteed.
Victor Sage
Victor Sage
20 Oct 2026
FleetPartners has agreed to a $1.131 billion cash takeover by SG Fleet after a competitive auction lifted the offer to $5.30 per share. The deal still requires shareholder, court and regulatory approval, with completion targeted for March 2027.
Victor Sage
Victor Sage
19 Oct 2026
Pacific Edge has secured new US payer access and a Veterans Administration purchasing agreement while proposed Medicare price increases could materially lift revenue per test. The recovery remains unfinished, however, with US commercial volumes down 13% and final Medicare coverage still pending.
Ada Torres
Ada Torres
19 Oct 2026
Arrow Minerals is seeking to expand its Pilbara iron ore footprint to more than 1,600 square kilometres through the Turee Creek acquisition and 12 new exploration applications. The land grab comes with historical high-grade results, but all relevant tenure remains pending and no resource has been defined.
Maxwell Dee
Maxwell Dee
16 Oct 2026
Mesoblast has reported a sharp commercial step-up in FY2026, with Ryoncil generating US$115.2 million in net sales and total revenue reaching US$120.3 million. The company has also completed treatment in its 350-patient back-pain trial and refinanced its debt, but remains loss-making and expects to need more capital beyond the next 12 months.
Ada Torres
Ada Torres
12 Oct 2026
EBR Systems reported 40 WiSE commercial implants in Q3, down from 46 in Q2 and below its prior forecast, as leadership changes and a sales strategy reset disrupted activity. Higher Medicare reimbursement and progress at its new manufacturing facility offer potential offsets, but both remain dependent on execution and regulatory approval.
Victor Sage
Victor Sage
12 Oct 2026
FBR has secured the remaining A$1.846 million of its A$4 million capital raising through a subscription with Alpine Capital, giving the robotics developer funding for Mantis testing, Hadrian deployment, debt repayment and working capital. The deal also brings further potential dilution through options and ends the company’s previous underwriting arrangement.
Victor Sage
Victor Sage
7 Oct 2026
An independent, Rhythm-funded economic model estimates its ColoSTAT blood test could avoid 29,427 public-hospital colonoscopies a year and deliver $72.4 million in net annual hospital savings. The figures strengthen Rhythm’s planned case for Medicare reimbursement, but remain modelled estimates rather than evidence from real-world use.
Ada Torres
Ada Torres
7 Oct 2026
Aurora Labs has appointed Andrew Garth as chief executive, moving former CEO Rebekah Letheby into a newly focused chief operating role. The reshuffle is intended to separate commercial strategy from technical execution as the company pursues scaled manufacturing and defence opportunities.
Victor Sage
Victor Sage
5 Oct 2026
6K Additive has completed a six-year, US$27.4 million secured loan with the US Export-Import Bank to expand production of critical metal powders in Pennsylvania. The financing gives the company access to project funding through June 2028, but the final interest rate and the expansion’s eventual output remain to be established.
Victor Sage
Victor Sage
2 Oct 2026

Browse the archive

Full archive